AP NEWS
This content is a press release from our partner ACCESSWIRE. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: ACCESSWIRE
This content is a press release from our partner ACCESSWIRE. The AP newsroom and editorial departments were not involved in its creation.

Avinger to Present at Oppenheimer Healthcare Conference on March 20

March 1, 2019
REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the

REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the Oppenheimer & Co. 29th Annual Healthcare Conference on Wednesday, March 20, 2019, at 1:00 pm Eastern Time, at the Westin New York Grand Central in New York City.

Management will be available to meet with investors throughout the day on Wednesday, March 20. Investors wishing to schedule a meeting should contact Oppenheimer & Co. or Avinger Investor Relations at .

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Investor Contact:

Mark Weinswig

Chief Financial Officer

Avinger, Inc.

(650) 241-7916

ir@avinger.com

Matt Kreps

Darrow Associates Investor Relations

(214) 597-8200

SOURCE: Avinger, Inc.